Aktual'nye voprosy kontrolya arterial'noy gipertenzii i narusheniya lipidnogo obmena: fokus na priverzhennost'


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of the study aimed to the assessment of effectiveness of therapy with a fixed combination of amlodipine and atorvastatin (Duplecor) in patients with arterial hypertension (AH) and associated dyslipidemia (DLE). It has been shown that the use of a fixed combination Duplecor is convenient, safe and effective approach to the simultaneous control of two major cardiovascular risk factors. Easy to administrate formulation - one tablet instead of two tablets - can greatly simplify the treatment of AH and DLE, and therefore improve patient’s adherence to drug therapy.

Full Text

Restricted Access

References

  1. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. (от имени исследователей DYSIS) Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012; 4: 1-10.
  2. Оганов Р.Г., Масленникова Г.А. Кардиология. 2007; 1: 4-7.
  3. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал. 2006; 4: 45-50.
  4. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России: информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3-7.
  5. Caro J.J., Jackson J., Speckman J. et al. Compliance as a function of initial choce of antihypertensive drug. Am. J. Hypertens. 1997; 10: 141A (Abstract).
  6. Cohn J.N., Wilson D.J., Neutel J., et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens. 2009; 22(2): 137-44.
  7. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. On behalf of the CARDS investigators. Pramary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diseases Stady (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004; 364: 685-96.
  8. Dahlof B., Sever P.S., Poulter N.R., et al. Preventon of cardiovascular events with an Antihypertensive regimen of amlodipin adding perindopril as required versus atenolol adding bendrofluazid as required, in Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005; 366: 895-906.
  9. Davis B.R., Furberg C.D., Wright J.T., et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967-75.
  10. Fogari R., Derosa G., Lazzari P., et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens. 2004; 17(9): 823-27.
  11. Ge C.J., Lu S.Z., Chen Y.D., et al. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels. 2008; 23(2): 91-95.
  12. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE ran-domised trial. Lancet. 2004; 363(9426): 2022-31.
  13. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291: 1071-80.
  14. Leibovitz E., Beniashvili M., Zimlichman R., et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 2003; 16(9Pt1): 715-18.
  15. Mason R.P., Kubant R., Heeba G. et al. Synergistic effect of amlodipine and atorvastatin in reversing LDL induced endothelial dysfunction. Pharm. Res. 2008; 25(8): 1798-806.
  16. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292(18): 2217-25.
  17. Patel B.V., Leslie R.S., Thiebaud P., et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc. Health Risk Manag. 2008; 4(3): 673-81.
  18. Pitt B., Byington R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000; 102: 1503-10.
  19. Sever P.S., Dahlof B., Poulter N.R., et al.; for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average holesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58.
  20. Simpson D.T., Erich S.R., Majumdar R.S., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333: 15
  21. Zamorano J., Edwards J. Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management. Integr. Blood Press Control. 2011: 55-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies